Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathy

Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy

Background: The diagnostic role of circulating anti-phospholipase A2 receptor antibodies (anti-PLA2R Abs) is now well recognized in idiopathic membranous nephropathy (iMN). These Abs could also be interesting as predictors of clinical outcome. In this study, we explored the prognostic value of anti-PLA2R Abs measured in a cohort of iMN patients, with a special focus on their ability to detect p...

Anti-phospholipase A2 receptor antibody in membranous nephropathy.

The M-type phospholipase A2 receptor (PLA2R) is a target autoantigen in adult idiopathic membranous nephropathy (MN), but the prevalence of autoantibodies against PLA2R is unknown among Chinese patients with MN. Here, we measured anti-PLA2R antibody in the serum of 60 patients with idiopathic MN, 20 with lupus-associated MN, 16 with hepatitis B (HBV)-associated MN, and 10 with tumor-associated ...

current concepts on anti-phospholipase a2 receptor antibody in idiopathic membranous nephropathy.

letter to the editor

Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.

In the 6 years since the discovery of anti-phospholipase A2 receptor (anti-PLA2R) antibodies in the majority of patients with primary membranous nephropathy (MN),1 our understanding of the role of anti-PLA2R in clinical disease has evolved rapidly. The initial small retrospective clinical studies indicated that anti-PLA2R levels could be modulated by immunosuppression.1,2 Levels decreased in ad...

Idiopathic membranous nephropathy and anti-phospholipase A2 receptor antibodies.